SAN DIEGO, Aug. 25 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA)
today announced the resignation of Harry D. Lambert from the Board of
Directors. Mr. Lambert, General Partner of InnoCal, a venture capital firm,
has been a member of the Board since 1994 when InnoCal first invested in Trega
as a private company. Mr. Lambert is resigning to concentrate on his and
InnoCal's other business interests.
"We are grateful for Harry's contribution during his tenure as Director,"
said Michael G. Grey, president and chief executive officer. "He has made
valued contributions to the development of Trega and we will miss his wise
counsel."
Trega Biosciences is focused on accelerating the process of drug discovery
from disease targets to clinical candidates by using small molecule
combinatorial chemistry, high throughput screening and predictive
bioinformatics to rapidly create novel drug candidates having greater chances
of clinical success. In combination with its wholly owned subsidiary,
NaviCyte, Trega offers integrated products and services spanning the drug
discovery process -- beginning with synthesizing novel compounds to providing
uniquely qualified drug leads -- to the pharmaceutical and biopharmaceutical
industries. Trega also uses its drug discovery technologies in its internal
development programs, which are focused on discovering small molecules acting
on melanocortin receptors, which may be important in the treatment of
inflammatory and metabolic diseases.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties. Trega disclaims, however, any intent or obligation
to update these forward-looking statements.
Trega's releases are on the World Wide Web at http://www.trega.com and PR
Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Vice President, Finance &
CFO of Trega Biosciences, 858-410-6695
|
